News
BITRF
0.0015
NaN%
--
Weekly Report: what happened at BITRF last week (1208-1212)?
Weekly Report · 3d ago
Biotron Limited’s BITO Securities Suspended by ASX
TipRanks · 4d ago
Biotron Limited Announces Quotation of New Securities on ASX
TipRanks · 12/10 07:03
Biotron Limited Announces Quotation of 500 Million Securities on ASX
TipRanks · 12/10 06:59
Biotron Limited Issues 500,000 Unquoted Performance Shares
TipRanks · 12/10 06:58
Biotron Completes Acquisition of Sedarex Limited
TipRanks · 12/10 06:58
Weekly Report: what happened at BITRF last week (1201-1205)?
Weekly Report · 12/08 09:22
Biotron Completes $1 Million Placement to Fund New Acquisition
TipRanks · 12/02 06:47
Weekly Report: what happened at BITRF last week (1124-1128)?
Weekly Report · 12/01 09:21
Biotron Limited Opens Non-Renounceable Entitlement Offer
TipRanks · 11/26 03:38
Weekly Report: what happened at BITRF last week (1117-1121)?
Weekly Report · 11/24 09:22
Biotron Limited Announces Details of Rights Issue
TipRanks · 11/19 06:27
Weekly Report: what happened at BITRF last week (1110-1114)?
Weekly Report · 11/17 09:22
Biotron Announces AGM Outcomes and Board Elections
TipRanks · 11/17 08:03
Biotron Pursues Growth with Sedarex Acquisition Amidst COVID-19 Trial Setback
TipRanks · 11/16 23:47
Biotron’s BIT-HBV001 Shows Promise in Hepatitis B Treatment
TipRanks · 11/13 22:25
Biotron Limited Engages Investors with Strategic Presentation
TipRanks · 11/11 01:28
Biotron’s Strategic Acquisition of Sedarex Limited Promises Growth
TipRanks · 11/11 00:07
Weekly Report: what happened at BITRF last week (1103-1107)?
Weekly Report · 11/10 09:21
Biotron Limited Announces Investor Webinar on Sedarex Acquisition
TipRanks · 11/07 03:08
More
Webull provides a variety of real-time BITRF stock news. You can receive the latest news about Biotron through multiple platforms. This information may help you make smarter investment decisions.
About BITRF
Biotron Limited is a clinical-stage biotechnology company. The Company is engaged in developing and commercializing a novel small molecule approach that has the potential to treat several serious viral diseases. Its proprietary primary bacterial cell-based screening platform enables rapid screening for target viroporin proteins, including hepatitis C, HIV-1, Dengue, Zika, Influenza, and Respiratory Syncytial Virus (RSV). The Company has developed a library of over 350 compounds with potential activity against a range of viral diseases. Its lead compound, BIT225, is in Phase II development for the treatment of HIV-1. BIT225 appears to inhibit HIV-1 replication in macrophage reservoir cells offering the potential, when used in combination with other anti-retroviral compounds, to eradicate HIV-1. The Company also owns SedRx, which is a general anesthetic containing alfaxalone.